Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBIT (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of EBIT data on record, last reported at -$16.9 million in Q3 2025.

  • For Q3 2025, EBIT fell 11.39% year-over-year to -$16.9 million; the TTM value through Sep 2025 reached -$66.3 million, down 4.31%, while the annual FY2024 figure was -$61.0 million, 34.17% up from the prior year.
  • EBIT reached -$16.9 million in Q3 2025 per SNTI's latest filing, down from -$16.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$1178.0 in Q1 2021 and bottomed at -$43.9 million in Q3 2023.
  • Average EBIT over 5 years is -$14.7 million, with a median of -$16.3 million recorded in 2024.
  • Peak YoY movement for EBIT: plummeted 998032.43% in 2022, then surged 65.32% in 2024.
  • A 5-year view of EBIT shows it stood at -$3.9 million in 2021, then plummeted by 334.42% to -$16.8 million in 2022, then fell by 11.34% to -$18.7 million in 2023, then increased by 13.54% to -$16.2 million in 2024, then fell by 4.83% to -$16.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$16.9 million in Q3 2025, -$16.8 million in Q2 2025, and -$16.4 million in Q1 2025.